Incyte stops phase 2 sub-study on ruxolitinib to treat colorectal cancer
A proposed interim analysis of the high C-reactive protein (CRP) subgroup showed that ruxolitinib plus regorafenib did not demonstrate a sufficient level of efficacy to warrant continuation. Incyte
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.